scispace - formally typeset
S

Stephen K. Frankel

Researcher at University of Colorado Denver

Publications -  51
Citations -  3092

Stephen K. Frankel is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Interstitial lung disease & Idiopathic pulmonary fibrosis. The author has an hindex of 26, co-authored 51 publications receiving 2553 citations. Previous affiliations of Stephen K. Frankel include University of Colorado Hospital & Anschutz Medical Campus.

Papers
More filters
Journal ArticleDOI

Mycophenolate Mofetil Improves Lung Function in Connective Tissue Disease-associated Interstitial Lung Disease

TL;DR: Small series suggest mycophenolate mofetil (MMF) is well tolerated and may be an effective therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD) and is associated with either stable or improved pulmonary physiology over a median 2.5 years of followup.
Journal ArticleDOI

Idiopathic Pleuroparenchymal Fibroelastosis: Description of a Novel Clinicopathologic Entity

TL;DR: In this paper, the authors characterized the clinical, radiographic, physiologic, and pathologic findings of a unique idiopathic pleuroparenchymal fibroelastosis.
Journal ArticleDOI

A Randomized Trial of an Intensive Physical Therapy Program for Patients with Acute Respiratory Failure

TL;DR: An intensive PT program did not improve long-term physical functional performance compared with a standard-of-care program and there were no differences in the total CS-PFP-10 scores at all three time points.
Journal ArticleDOI

Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease

TL;DR: Data from this study suggest that in rheumatoid-arthritis associated interstitial lung disease, disease progression and survival differ between subgroups defined by HRCT pattern; however, when controlling for potentially influential variables, pulmonary physiology, but notHRCT pattern, independently predicts mortality.
Journal ArticleDOI

Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.

TL;DR: MMF appears to be safe and well tolerated in patients with CTD-ILD, and larger-scale studies are needed to further evaluate the efficacy of MMF in this patient population.